Last reviewed · How we verify
Transdermal Teriparatide
At a glance
| Generic name | Transdermal Teriparatide |
|---|---|
| Also known as | synthetic human parathyroid hormone (shPTH) (1-34), synthetic human teriparatide |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Study of AK159 in Healthy Postmenopausal Women (PHASE1)
- Clinical Study of AK159 in Healthy Postmenopausal Women (PHASE1)
- A Study for the Transdermal Application of Teriparatide (PHASE2)
- A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women (PHASE1)
- Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |